Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OLYMPIA-2: odronextamab plus chemotherapy versus rituximab plus chemotherapy in previously untreated follicular lymphoma
2022-502113-28-00Phase 3Authorised
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Oct 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 17
01
Overview
Phase 3, randomised, open-label trial of odronextamab in follicular lymphoma (FL) (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Incidence of dose-limiting toxicities, Incidence of treatment-emergent adverse events and 2 more. Planned start Oct 2023; status: authorised.
02
Drugs
odronextamab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2022-502113-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502113-28-00.